GSK-207626

Study Sponsor: GSK

Study Title

A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in participants with chronic obstructive pulmonary disease

Medicine or Vaccine (generic name)

fluticasone furoate/vilanterol/umeclidinium bromide

Sponsor Identification Number

207626

Trial Registry Identification Number(#'s)

NCT03474081

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 4

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=207626

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03474081

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001190-16

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

June 2021